"This has resulted in the PBAC drawing conclusions about the cost-effectiveness of ORKAMBI which Vertex disagrees with and believes is based on a flawed analysis of available data," said the company. …
Vertex: Conclusions based on a 'flawed analysis of available data'
April 18, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Medicines Australia chief says next negotiation is about getting comfortable with being uncomfortable
July 3, 2026 - - Latest News -
New once weekly therapy offers extended protection for people with haemophilia A
July 3, 2026 - - Latest News -
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Nothing else grows below this self-serving and broken institutional framework
July 3, 2026 - - Latest News -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News